HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDI Notification Costs Estimate, P&G Board: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

FDA NDI notification costs estimate unchanged; P&G proxy vote update favors Peltz; and trio of advertising violations for California supplement, skin care firms.

You may also be interested in...

More Health Care Products Offered In Latest 'Free Trial' Scam FTC Targets

Products offered in online scams that lead to monthly bills usually are “something that the average person is going to be looking for, a renewal product like vitamins, tooth whitener and skin cream," says an FTC attorney. Federal judge halts sales by Triangle Media and associated companies and freezes their assets after FTC showed “immediate and irreparable injury, loss or damage” to consumers.

NDI Notification Estimate Unchanged: Health And Wellness Industry News

Biotek gets FDA's own-labeler lesson; MyNicNaxs shut down after ignoring warning; and FDA sticks with NDI notification cost estimate.

FTC Curbs Another 'Free' Ride: Health And Wellness Industry News

Health Research Laboratories agrees to settle an FTC complaint alleging false "free" offers on top of bogus health claims; reports that biotin can interfere with certain lab tests are reminders for consumers to tell doctors about supplements they use, says CRN; kratom group asks FDA and states "to tone down their overheated rhetoric about the non-opiate botanical"; and health and wellness recalls.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts